Latest Insider Transactions at Decibel Therapeutics, Inc. (DBTX)
This section provides a real-time view of insider transactions for Decibel Therapeutics, Inc. (DBTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Decibel Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Decibel Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 25
2023
|
Anna Trask Chief People Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
106,864
-100.0%
|
-
|
|
Sep 25
2023
|
Alison Cecily Finger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Sep 25
2023
|
John Jui Jen Lee Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
147,144
-100.0%
|
-
|
|
Sep 25
2023
|
William H. Carson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Sep 25
2023
|
Matthew C Kapusta Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-100.0%
|
-
|
|
Sep 25
2023
|
Laurence Reid Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
220,849
-100.0%
|
-
|
|
Sep 25
2023
|
Kevin F Mclaughlin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Sep 25
2023
|
Sara Nochur Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Jun 13
2023
|
Alison Cecily Finger Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Jun 13
2023
|
William H. Carson Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Jun 13
2023
|
Sara Nochur Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Jun 13
2023
|
Kevin F Mclaughlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Mar 19
2023
|
Matthew C Kapusta Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Mar 16
2023
|
Laurence Reid Director |
BUY
Grant, award, or other acquisition
|
Direct |
195,000
+46.89%
|
-
|
|
Jan 26
2023
|
John Jui Jen Lee Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+44.92%
|
-
|
|
Jan 26
2023
|
Anna Trask Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+49.56%
|
-
|
|
Jan 03
2022
|
Anna Trask Chief People Officer |
SELL
Open market or private sale
|
Direct |
378
-8.43%
|
$1,890
$5.04 P/Share
|
|
Dec 02
2021
|
Anna Trask Chief People Officer |
SELL
Open market or private sale
|
Direct |
5,291
-39.82%
|
$31,746
$6.36 P/Share
|
|
Nov 03
2021
|
Anna Trask Chief People Officer |
SELL
Open market or private sale
|
Direct |
378
-4.78%
|
$3,024
$8.34 P/Share
|
|
Nov 02
2021
|
Anna Trask Chief People Officer |
SELL
Open market or private sale
|
Direct |
4,913
-38.31%
|
$39,304
$8.31 P/Share
|
|
Oct 14
2021
|
Anna Trask Chief People Officer |
SELL
Open market or private sale
|
Direct |
5,364
-29.49%
|
$37,548
$7.55 P/Share
|
|
Sep 15
2021
|
Laurence Reid Director |
BUY
Open market or private purchase
|
Direct |
10,000
+27.89%
|
$70,000
$7.64 P/Share
|
|
Feb 17
2021
|
Adveq Technology Ix S.C.S. Schroder > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,048,656
+50.0%
|
-
|
|
Feb 17
2021
|
Neil Exter Director |
BUY
Conversion of derivative security
|
Indirect |
3,092,516
+18.14%
|
-
|
|
Feb 17
2021
|
Peter A. Thompson Director |
BUY
Open market or private purchase
|
Indirect |
1,666,666
+30.52%
|
$29,999,988
$18.0 P/Share
|
|
Feb 17
2021
|
Peter A. Thompson Director |
BUY
Conversion of derivative security
|
Indirect |
3,278,526
+50.0%
|
-
|
|
Feb 17
2021
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
575,000
+33.89%
|
$10,350,000
$18.0 P/Share
|
|
Feb 17
2021
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
546,421
+50.0%
|
-
|
|
Feb 17
2021
|
Matthew Foy Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+11.25%
|
$2,700,000
$18.0 P/Share
|
|
Feb 17
2021
|
Matthew Foy Director |
BUY
Conversion of derivative security
|
Indirect |
1,033,663
+33.34%
|
-
|
|
Feb 17
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,666,666
+30.52%
|
$29,999,988
$18.0 P/Share
|
|
Feb 17
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
3,278,526
+50.0%
|
-
|
|
Feb 17
2021
|
Glaxosmithkline PLC Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+11.25%
|
$2,700,000
$18.0 P/Share
|
|
Feb 17
2021
|
Glaxosmithkline PLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,033,663
+33.34%
|
-
|
|
Feb 17
2021
|
Longevity Fund 2 LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
79,143
+50.0%
|
-
|
|
Feb 17
2021
|
Regeneron Pharmaceuticals, Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,097,314
+50.0%
|
-
|
|
Feb 17
2021
|
Gv 2016 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
321,978
+50.0%
|
-
|
|
Feb 17
2021
|
Gv 2017 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
494,649
+50.0%
|
-
|
|
Feb 17
2021
|
Gv 2019 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
819,631
+50.0%
|
-
|